PDCD1 and toxic epidermal necrolysis: Clinical evidence has shown that PD-1 inhibitors can induce immune-related cutaneous adverse events (irCAEs), among which toxic epidermal necrolysis (TEN) is a rare yet life-threatening subtype with an incidence of less than 0.1% (8).